Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
View Full LandscapeTarget Indication
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Clinical Trial
NCT02674750Last updated: 2/15/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.